AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10596994 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold blood cardioplegia (B, n = 10)
Number of subjects: 20
Study 10596994 — intervention group
Group type: COMPARATOR
Intervention: Cold crystalloid cardioplegia (C, n = 10)
Number of subjects: 20
Study 8768182 — intervention group
Group type: EXPERIMENTAL
Intervention: Polar projection
Number of subjects: 0
Study 8768182 — intervention group
Group type: COMPARATOR
Intervention: Parallel projection
Number of subjects: 0
Study 8768182 — intervention group
Group type: COMPARATOR
Intervention: Random mechanism
Number of subjects: 0
Study 1992363 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymptomatic (AS+)
Number of subjects: 18
Study 1992363 — intervention group
Group type: EXPERIMENTAL
Intervention: AIDS/ARC
Number of subjects: 18
Study 7141754 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (20 mg rectal pretreatment)
Number of subjects: 8
Study 7141754 — intervention group
Group type: COMPARATOR
Intervention: Placebo pretreatment
Number of subjects: 8
Study 7141754 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolfenamic acid (300 mg)
Number of subjects: 8
Study 31924519 — intervention group
Group type: EXPERIMENTAL
Intervention: Early rehabilitation (immediate physical therapy for passive and active ROM)
Number of subjects: 107
Study 31924519 — intervention group
Group type: COMPARATOR
Intervention: Delayed rehabilitation (no ROM for 6 weeks)
Number of subjects: 107
Study 30036672 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofazimine (100 mg per day)
Number of subjects: 156
Study 30036672 — intervention group
Group type: COMPARATOR
Intervention: Control regimen
Number of subjects: 156
Study 28193599 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low-carbohydrate ketogenic diet and lifestyle recommendations (n=12)
Number of subjects: 25
Study 25963775 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervision (tele‐conferencing or tape‐based)
Number of subjects: 96
Study 25963775 — intervention group
Group type: COMPARATOR
Intervention: Workshop only
Number of subjects: 96
Study 23377024 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 0 mg (no caffeine) with 4.3% alcohol
Number of subjects: 146
Study 23377024 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 62.5 mg with 4.3% alcohol
Number of subjects: 146
Study 23377024 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 125 mg with 4.3% alcohol
Number of subjects: 146
Study 23377024 — intervention group
Group type: COMPARATOR
Intervention: Caffeine 0 mg (no caffeine) with no alcohol
Number of subjects: 146
Study 23377024 — intervention group
Group type: COMPARATOR
Intervention: Caffeine 62.5 mg with no alcohol
Number of subjects: 146
Study 23377024 — intervention group
Group type: COMPARATOR
Intervention: Caffeine 125 mg with no alcohol
Number of subjects: 146
Study 21549138 — intervention group
Group type: EXPERIMENTAL
Intervention: 70% cocoa chocolate
Number of subjects: 280
Study 21549138 — intervention group
Group type: EXPERIMENTAL
Intervention: 85% cocoa chocolate
Number of subjects: 280
Study 21549138 — intervention group
Group type: COMPARATOR
Intervention: white chocolate (control)
Number of subjects: 280
Study 21549138 — intervention group
Group type: EXPERIMENTAL
Intervention: chocolate samples with high sugar and cocoa content
Number of subjects: 280
Study 19767090 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestrogen plus progestin (0.625 mg conjugated equine oestrogen plus 2.5 mg medroxyprogesterone acetate)
Number of subjects: 16608
Study 19767090 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16608
Study 17573745 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral Gln (1 g/kg/day) with enteral nutrition (Ensure)
Number of subjects: 109
Study 17573745 — intervention group
Group type: COMPARATOR
Intervention: Control group received only enteral nutrition (Ensure)
Number of subjects: 109
Study 14739803 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine at 200 ng/ml (analgesic, subanesthetic)
Number of subjects: 8
Study 14739803 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine at 50 ng/ml (subanalgesic)
Number of subjects: 8
Study 14739803 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 8
Study 11770699 — intervention group
Group type: EXPERIMENTAL
Intervention: C(-444) allele
Number of subjects: 119
Study 11770699 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 119
Study 9248315 — intervention group
Group type: EXPERIMENTAL
Intervention: MOS SF‐36 Health Survey (SF‐36)
Number of subjects: 163
Study 8507122 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 20 mg twice daily
Number of subjects: 311
Study 8507122 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg twice daily
Number of subjects: 311
Study 8507122 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestyramine 24 g daily
Number of subjects: 311
Study 8507122 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestyramine 12 g twice daily with Pravastatin 40 mg
Number of subjects: 311
Study 8507122 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 40 or 80 mg daily
Number of subjects: 311
Study 8507122 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestyramine alone
Number of subjects: 311
Study 8507122 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (Cholestyramine + Pravastatin)
Number of subjects: 311
Study 8507122 — intervention group
Group type: EXPERIMENTAL
Intervention: All regimens
Number of subjects: 311
Study 8507122 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 311
Study 8507122 — intervention group
Group type: COMPARATOR
Intervention: All treatment groups
Number of subjects: 311
Study 3034026 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril 5 mg
Number of subjects: 10
Study 3034026 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril 10 mg
Number of subjects: 10
Study 3034026 — intervention group
Group type: COMPARATOR
Intervention: Captopril 12.5 mg
Number of subjects: 10
Study 3034026 — intervention group
Group type: COMPARATOR
Intervention: Captopril 25 mg
Number of subjects: 10
Study 3034026 — intervention group
Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 10
Study 29996833 — intervention group
Group type: COMPARATOR
Intervention: Post-discharge malaria chemoprevention (PMC) with antimalarial drugs for 3 months post-discharge.
Number of subjects: 0
Study 29996833 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based delivery of PMC.
Number of subjects: 0
Study 29996833 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of health cards for treatment reminders.
Number of subjects: 0
Study 29996833 — intervention group
Group type: EXPERIMENTAL
Intervention: Text message reminders for PMC delivery.
Number of subjects: 0
Study 29996833 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine as the antimalarial drug.
Number of subjects: 0
Study 26939695 — intervention group
Group type: EXPERIMENTAL
Intervention: Community health worker (CHW) hang-up visits at intervals of 1-3, 5-7, 10-12, 15-17 days
Number of subjects: 540
Study 26939695 — intervention group
Group type: EXPERIMENTAL
Intervention: Community health worker (CHW) hang-up visits
Number of subjects: 540
Study 26939695 — intervention group
Group type: COMPARATOR
Intervention: No CHW hang-up visit (control group)
Number of subjects: 540
Study 25079863 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate (LC)
Number of subjects: 143
Study 25079863 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 143
Study 22220768 — intervention group
Group type: EXPERIMENTAL
Intervention: GBR procedure
Number of subjects: 91
Study 22220768 — intervention group
Group type: COMPARATOR
Intervention: Non-GBR procedure
Number of subjects: 91
Study 20513271 — intervention group
Group type: EXPERIMENTAL
Intervention: FIN‐D2D lifestyle intervention in primary health-care
Number of subjects: 0
Study 20513271 — intervention group
Group type: EXPERIMENTAL
Intervention: FINNAIR workplace-targeted intervention
Number of subjects: 0
Study 20513271 — intervention group
Group type: EXPERIMENTAL
Intervention: GOAL community-based prevention programme
Number of subjects: 0
Study 18480672 — intervention group
Group type: EXPERIMENTAL
Intervention: Upstream tirofiban therapy
Number of subjects: 172
Study 18480672 — intervention group
Group type: EXPERIMENTAL
Intervention: Downstream tirofiban therapy
Number of subjects: 172
Study 18480672 — intervention group
Group type: COMPARATOR
Intervention: Control group (primary PCI treatment alone)
Number of subjects: 172
Study 15706546 — intervention group
Group type: EXPERIMENTAL
Intervention: Leg-loading exercise protocol (5 progression levels)
Number of subjects: 18
Study 14520850 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 25 mg twice a day
Number of subjects: 104
Study 14520850 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 25-50 mg twice a day
Number of subjects: 104
Study 14520850 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol 5-10 mg once a day
Number of subjects: 104
Study 11755543 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (n = 105)
Number of subjects: 211
Study 11755543 — intervention group
Group type: EXPERIMENTAL
Intervention: External pneumatic compression (n = 106)
Number of subjects: 211
Study 9371346 — intervention group
Group type: EXPERIMENTAL
Intervention: Saquinavir
Number of subjects: 300
Study 9371346 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple combination (saquinavir, zidovudine, zalcitabine)
Number of subjects: 300
Study 9371346 — intervention group
Group type: COMPARATOR
Intervention: Saquinavir and zidovudine combination
Number of subjects: 300
Study 9371346 — intervention group
Group type: EXPERIMENTAL
Intervention: Zalcitabine
Number of subjects: 300
Study 1531855 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) alone
Number of subjects: 144
Study 1531855 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) combined with chemotherapy
Number of subjects: 144
Study 1531855 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 144
Study 3758141 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 100 mg/day
Number of subjects: 48
Study 3758141 — intervention group
Group type: COMPARATOR
Intervention: Conventional diuretic therapy
Number of subjects: 48
Study 31663690 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (2 μg kg‐1 perioperatively)
Number of subjects: 24
Study 31663690 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 24
Study 29339594 — intervention group
Group type: EXPERIMENTAL
Intervention: Crenotherapy (group B)
Number of subjects: 98
Study 29339594 — intervention group
Group type: COMPARATOR
Intervention: Treadmill exercise (group A)
Number of subjects: 98
Study 29339594 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 98
Study 25201095 — intervention group
Group type: EXPERIMENTAL
Intervention: Animal-assisted therapy (therapy dog visitation for 15 minutes before physical therapy)
Number of subjects: 72
Study 25201095 — intervention group
Group type: COMPARATOR
Intervention: Standard postoperative physical therapy regimens
Number of subjects: 72
Study 23513398 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertical position
Number of subjects: 164
Study 23513398 — intervention group
Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 164
Study 20934440 — intervention group
Group type: EXPERIMENTAL
Intervention: 22mg yohimbine hydrochloride
Number of subjects: 14
Study 20934440 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 19454916 — intervention group
Group type: EXPERIMENTAL
Intervention: Eight-session parent intervention
Number of subjects: 71
Study 19454916 — intervention group
Group type: COMPARATOR
Intervention: Waitlist (Control)
Number of subjects: 71
Study 16434463 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% lipid/heparin infusion
Number of subjects: 8
Study 16434463 — intervention group
Group type: COMPARATOR
Intervention: saline/heparin infusion
Number of subjects: 8
Study 15232330 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 80 mg/d
Number of subjects: 0
Study 15232330 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 40 mg/d
Number of subjects: 0
Study 15232330 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine 20 mg/d
Number of subjects: 0
Study 11306523 — intervention group
Group type: EXPERIMENTAL
Intervention: AMI patients
Number of subjects: 135
Study 11306523 — intervention group
Group type: EXPERIMENTAL
Intervention: UAP patients
Number of subjects: 135
Study 11306523 — intervention group
Group type: EXPERIMENTAL
Intervention: SAP patients
Number of subjects: 135
Study 11306523 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 135
Study 11306523 — intervention group
Group type: EXPERIMENTAL
Intervention: UAP patients (in atherectomy specimens)
Number of subjects: 135
Study 9645896 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous flecainide (1.5 mg/kg body weight, maximum 150 mg)
Number of subjects: 106
Study 9645896 — intervention group
Group type: COMPARATOR
Intervention: Intravenous sotalol (1.5 mg/kg body weight, maximum 150 mg)
Number of subjects: 106
Study 7840710 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive therapy including indomethacin, essential and dimephosphone
Number of subjects: 70
Study 7840710 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined use of pathogenetic and antibacterial drugs (monomycin, kanamycin, polymyxin, gentamicin)
Number of subjects: 70
Study 2906248 — intervention group
Group type: EXPERIMENTAL
Intervention: N‐696 (30 mg/d for 7 days)
Number of subjects: 14
Study 2906248 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (60 mg/d for 7 days)
Number of subjects: 14
Study 1850964 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (100 mg)
Number of subjects: 11
Study 1850964 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 1092749 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate 20 mg daily
Number of subjects: 44
Study 1092749 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 30655188 — intervention group
Group type: EXPERIMENTAL
Intervention: Living in nursing home
Number of subjects: 72
Study 30655188 — intervention group
Group type: COMPARATOR
Intervention: Living in own home
Number of subjects: 72
Study 30655188 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased ultraviolet index exposure
Number of subjects: 72
Study 30232597 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin 1200 mg for 14 days
Number of subjects: 23
Study 30232597 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 23
Study 29201297 — intervention group
Group type: EXPERIMENTAL
Intervention: Polmacoxib 2 mg
Number of subjects: 362
Study 29201297 — intervention group
Group type: COMPARATOR
Intervention: Celecoxib 200 mg
Number of subjects: 362
Study 29201297 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 362
Study 25311357 — intervention group
Group type: EXPERIMENTAL
Intervention: DWP450 (20 U)
Number of subjects: 268
Study 25311357 — intervention group
Group type: COMPARATOR
Intervention: OBoNT (20 U)
Number of subjects: 268
Study 25311357 — intervention group
Group type: COMPARATOR
Intervention: DWP450 and OBoNT
Number of subjects: 268
Study 23819122 — intervention group
Group type: EXPERIMENTAL
Intervention: Mydriasert insert (0.28 mg of tropicamide and 5.4 mg of phenylephrine hydrochloride)
Number of subjects: 70
Study 23819122 — intervention group
Group type: COMPARATOR
Intervention: Conventional mydriatic drops (tropicamide 1%, phenylephrine 10%, and cyclopentolate 1%)
Number of subjects: 70
Study 23819122 — intervention group
Group type: EXPERIMENTAL
Intervention: Mydriasert insert
Number of subjects: 70
Study 23819122 — intervention group
Group type: COMPARATOR
Intervention: Conventional mydriatic drops
Number of subjects: 70
Study 23819122 — intervention group
Group type: EXPERIMENTAL
Intervention: Mydriasert insert and Conventional mydriatic drops
Number of subjects: 70
Study 21577031 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized liposomal amphotericin B (lipAmB)
Number of subjects: 98
Study 21577031 — intervention group
Group type: COMPARATOR
Intervention: Historical control group
Number of subjects: 98
Study 19922034 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise using Dance Dance Revolution (DDR) for 12 weeks
Number of subjects: 35
Study 19922034 — intervention group
Group type: COMPARATOR
Intervention: Non-exercising delayed-treatment control group (DTC)
Number of subjects: 35
Study 16773694 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (two 600 mg doses orally 24 and 12 hours before ERCP and 600 mg IV, twice a day for two days after ERCP)
Number of subjects: 106
Study 16773694 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline (IV, twice a day for two days after ERCP)
Number of subjects: 106
Study 16773694 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Number of subjects: 106
Study 16773694 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline
Number of subjects: 106
Study 15519704 — intervention group
Group type: EXPERIMENTAL
Intervention: Viatim vaccine
Number of subjects: 0
Study 15519704 — intervention group
Group type: COMPARATOR
Intervention: Hepatyrix vaccine
Number of subjects: 0
Study 11760147 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ondansetron (8 mg PO every 8 hours)
Number of subjects: 102
Study 11760147 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral granisetron (1 mg PO every 12 hours)
Number of subjects: 102
Study 11760147 — intervention group
Group type: EXPERIMENTAL
Intervention: IV ondansetron (32 mg IV every 24 hours)
Number of subjects: 102
Study 11760147 — intervention group
Group type: COMPARATOR
Intervention: Cost analysis among all arms
Number of subjects: 102
Study 9919425 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (three times a week)
Number of subjects: 0
Study 9919425 — intervention group
Group type: COMPARATOR
Intervention: Control group (continued regular treatment)
Number of subjects: 0
Study 8115153 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral melatonin treatment
Number of subjects: 19
Study 8115153 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 19
Study 3043418 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine consumption
Number of subjects: 10064
Study 3043418 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking
Number of subjects: 10064
Study 31335363 — intervention group
Group type: EXPERIMENTAL
Intervention: Venoarterial extracorporeal membrane oxygenation with concomitant Impella (ECPELLA)
Number of subjects: 425
Study 31335363 — intervention group
Group type: COMPARATOR
Intervention: Venoarterial extracorporeal membrane oxygenation (VA ECMO) alone
Number of subjects: 425
Study 30036177 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose for pre-operative haemoglobin optimisation
Number of subjects: 20000
Study 30036177 — intervention group
Group type: COMPARATOR
Intervention: Non-optimisation control arm
Number of subjects: 20000
Study 27214731 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonoscopy screening
Number of subjects: 94459
Study 27214731 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard air insufflation
Number of subjects: 94459
Study 27214731 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon dioxide (CO2) insufflation
Number of subjects: 94459
Study 25622725 — intervention group
Group type: EXPERIMENTAL
Intervention: Tooth brushing + mouth washing with chlorine dioxide + tongue cleaning
Number of subjects: 30
Study 25622725 — intervention group
Group type: EXPERIMENTAL
Intervention: Tooth brushing + mouth washing with chlorine dioxide
Number of subjects: 30
Study 25622725 — intervention group
Group type: COMPARATOR
Intervention: Tooth brushing alone
Number of subjects: 30
Study 24104372 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant gemcitabine treatment (1g/m2 d 1, 8, 15, q 4 weeks for 6 months)
Number of subjects: 368
Study 24104372 — intervention group
Group type: COMPARATOR
Intervention: Observation alone
Number of subjects: 368
Study 24104372 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant gemcitabine treatment
Number of subjects: 368
Study 20628405 — intervention group
Group type: EXPERIMENTAL
Intervention: 140 mg silybin (Legalon Forte) with a vegetarian meal containing 13.9 mg iron
Number of subjects: 10
Study 20628405 — intervention group
Group type: COMPARATOR
Intervention: 200 ml water
Number of subjects: 10
Study 20628405 — intervention group
Group type: COMPARATOR
Intervention: 200 ml tea
Number of subjects: 10
Study 18172039 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet plus pravastatin 10 to 20 mg/d
Number of subjects: 5356
Study 18172039 — intervention group
Group type: COMPARATOR
Intervention: Diet alone
Number of subjects: 5356
Study 18172039 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet plus pravastatin 10 to 20 mg/d (women ≥ 60 years)
Number of subjects: 5356
Study 18172039 — intervention group
Group type: COMPARATOR
Intervention: Diet alone (women ≥ 60 years)
Number of subjects: 5356
Study 16948756 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination group (amiodarone 5 mg/kg and MgSO(4) 1.5 g)
Number of subjects: 136
Study 16948756 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone group (amiodarone 5 mg/kg)
Number of subjects: 136
Study 16948756 — intervention group
Group type: COMPARATOR
Intervention: Control group (saline)
Number of subjects: 136
Study 14558738 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefaclor 375 mg twice daily
Number of subjects: 300
Study 14558738 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin 250 mg twice daily
Number of subjects: 300
Study 11166781 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronised fenofibrate
Number of subjects: 35
Study 9505239 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein enriched product
Number of subjects: 50
Study 9505239 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate product
Number of subjects: 50
Study 7913970 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole treatment for 1 to 4 months
Number of subjects: 0
Study 7913970 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole treatment for 4 months
Number of subjects: 0
Study 7913970 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole treatment for 1-22 months
Number of subjects: 0